Prothena Plc Share Price (NASDAQ: PRTA)

$8.76

▲

0.2

(2.34%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Prothena Plc Stock chart to analyse performance

Prothena Plc stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$8.55
Today's High:$8.97
$8.76
2.4%
Downside
Day's Volatility :4.68%
Upside
2.34%
52 Weeks Low:$4.32
52 Weeks High:$22.83
$8.76
50.68%
Downside
52 Weeks Volatility :81.08%
Upside
61.63%

Prothena Plc Stock Returns

Period	Prothena Corporation Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	91.7%	6.0%	0.0%
6 Months	-42.35%	-5.6%	0.0%
1 Year	-60.05%	-11.1%	0.0%
3 Years	-71.0%	6.8%	-7.8%

Prothena Corporation Plc Key Stats

Check Prothena Plc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$8.56
Open	$8.58
Today's High	$8.97
Today's Low	$8.55
Market Capitalization	$460.8M
Today's Volume	$1.2M
52 Week High	$22.83
52 Week Low	$4.32
Revenue TTM	$10.3M
EBITDA	$-248.1M
Earnings Per Share (EPS)	$-5.62
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-66.85%

Stock Returns calculator for Prothena Plc Stock including INR - Dollar returns

The Prothena Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Prothena Plc investment value today

Current value as on today

₹44,170

Returns

₹55,830

(-55.83%)

Returns from Prothena Plc Stock

₹60,146 (-60.15%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Prothena Plc Stock

-47%

Period: Jul 24, 2025 to Aug 23, 2025. Change in 30 Days versus previous period

Search interest for Prothena Plc Stock from India on INDmoney has decreased by -47% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Prothena Corporation Plc

Name
Holdings %
Name
Holdings %
FMR Inc
14.75%
BlackRock Inc
7.51%
Armistice Capital, LLC
4.08%
Vanguard Group Inc
4.04%
Palo Alto Investors, LLC
3.08%
State Street Corp
2.83%

Analyst Recommendation on Prothena Plc Stock

Rating

Trend

Buy

76%Buy

23%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Prothena Plc(by analysts ranked 0 to 5 stars)

Prothena Plc Share Price Target

What analysts predicted

Upside of 196.8%

Target:

$26.00

Current:

$8.76

Prothena Plc share price target is $26.00, a slight Upside of 196.8% compared to current price of $8.76 as per analysts' prediction.

Prothena Plc Stock Insights

Price Movement
In the last 1 month, PRTA stock has moved up by 29.9%
Increasing Revenue
Revenue is up for the last 4 quarters, 970.0K → 4.42M (in $), with an average increase of 38.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -57.95M → -125.76M (in $), with an average decrease of 56.4% per quarter
PRTA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.6% return, outperforming this stock by 126.2%
PRTA vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 109.5% return, outperforming this stock by 180.5%
Price to Sales
ForPRTA every $1 of sales, investors are willing to pay $45.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Prothena Corporation Plc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$814.0K	↓ 14.76%
Net Income	$-77.7M	↓ 50.09%
Net Profit Margin	-9.5K%	↑ 6755.28%

	FY20	Y/Y Change
Revenue	$853.0K	↑ 4.79%
Net Income	$-111.1M	↑ 43.08%
Net Profit Margin	-13.0K%	↓ 3487.15%

	FY21	Y/Y Change
Revenue	$200.6M	↑ 23414.3%
Net Income	$67.0M	↓ 160.26%
Net Profit Margin	33.39%	↑ 13063.17%

	FY22	Y/Y Change
Revenue	$53.9M	↓ 73.13%
Net Income	$-116.9M	↓ 274.62%
Net Profit Margin	-216.95%	↓ 250.34%

	FY23	Y/Y Change
Revenue	$91.4M	↑ 69.5%
Net Income	$-147.0M	↑ 25.72%
Net Profit Margin	-160.91%	↑ 56.04%

	FY24	Y/Y Change
Revenue	$135.2M	↑ 47.92%
Net Income	$-122.3M	↓ 16.81%
Net Profit Margin	-90.49%	↑ 70.42%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$50.0K	↓ 84.18%
Net Income	$-72.2M	↑ 7.06%
Net Profit Margin	-144.5K%	↓ 123124.84%

	Q2 FY24	Q/Q Change
Revenue	$132.0M	↑ 263928.0%
Net Income	$66.9M	↓ 192.59%
Net Profit Margin	50.67%	↑ 144528.67%

	Q3 FY24	Q/Q Change
Revenue	$970.0K	↓ 99.27%
Net Income	$-59.0M	↓ 188.21%
Net Profit Margin	-6.1K%	↓ 6133.25%

	Q4 FY24	Q/Q Change
Revenue	$2.1M	↑ 118.87%
Net Income	$-58.0M	↓ 1.77%
Net Profit Margin	-2.7K%	↑ 3352.67%

	Q1 FY25	Q/Q Change
Revenue	$2.8M	↑ 33.21%
Net Income	$-60.2M	↑ 3.86%
Net Profit Margin	-2.1K%	↑ 601.37%

	Q2 FY25	Q/Q Change
Revenue	$4.4M	↑ 56.29%
Net Income	$-125.8M	↑ 108.93%
Net Profit Margin	-2.8K%	↓ 716.87%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-50.0M	↓ 50.09%

	FY20	Y/Y Change
Profit	$853.0K	↓ 101.71%

	FY21	Y/Y Change
Profit	$200.6M	↑ 23414.3%

	FY22	Y/Y Change
Profit	$53.9M	↓ 73.13%

	FY23	Y/Y Change
Profit	$-129.2M	↓ 339.68%

	FY24	Y/Y Change
Profit	$135.2M	↓ 204.61%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-837.0K	↓ 94.01%

	Q2 FY24	Q/Q Change
Profit	$74.5M	↓ 9001.31%

	Q3 FY24	Q/Q Change
Profit	$970.0K	↓ 98.7%

	Q4 FY24	Q/Q Change
Profit	$1.2M	↑ 24.74%

	Q1 FY25	Q/Q Change
Profit	$2.8M	↑ 133.72%

	Q2 FY25	Q/Q Change
Profit	$4.4M	↑ 56.29%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-53.0M	↑ 87.33%
Investing Cash Flow	$-547.0K	↓ 68.36%
Financing Cash Flow	$228.0K	↓ 99.43%

	FY20	Y/Y Change
Operating Cash Flow	$-80.4M	↑ 51.72%
Investing Cash Flow	$-196.0K	↓ 64.17%
Financing Cash Flow	$215.0K	↓ 5.7%

	FY21	Y/Y Change
Operating Cash Flow	$92.6M	↓ 215.23%
Investing Cash Flow	$-575.0K	↑ 193.37%
Financing Cash Flow	$190.3M	↑ 88426.51%

	FY22	Y/Y Change
Operating Cash Flow	$-108.8M	↓ 217.51%
Investing Cash Flow	$-464.0K	↓ 19.3%
Financing Cash Flow	$241.5M	↑ 26.86%

	FY23	Y/Y Change
Operating Cash Flow	$-133.9M	↑ 23.05%
Investing Cash Flow	$-2.8M	↑ 497.63%
Financing Cash Flow	$45.1M	↓ 81.32%

	FY24	Y/Y Change
Operating Cash Flow	$-150.1M	↑ 12.06%
Investing Cash Flow	$-298.0K	↓ 89.25%
Financing Cash Flow	$1.6M	↓ 96.55%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-73.1M	↑ 43.13%
Investing Cash Flow	$-103.0K	↓ 93.19%
Financing Cash Flow	$836.0K	↑ 73.08%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$16.2M	↓ 122.16%
Investing Cash Flow	$-143.0K	↑ 38.83%
Financing Cash Flow	$444.0K	↓ 46.89%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-45.2M	↓ 379.15%
Investing Cash Flow	$-9.0K	↓ 93.71%
Financing Cash Flow	$333.0K	↓ 25.0%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-47.8M	↑ 5.72%
Investing Cash Flow	$-43.0K	↑ 377.78%
Financing Cash Flow	$-59.0K	↓ 117.72%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-53.4M	↑ 11.7%
Investing Cash Flow	$-42.0K	↓ 2.33%
Financing Cash Flow	$-48.0K	↓ 18.64%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-50.2M	↓ 5.95%
Investing Cash Flow	$-90.9K	↑ 116.52%
Financing Cash Flow	$-78.7K	↑ 63.97%

Prothena Plc Technicals Summary

Sell

Neutral

Buy

Prothena Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Prothena Corporation Plc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Prothena Corporation Plc	31.44%	-42.35%	-60.05%	-71.0%	-32.31%
Regeneron Pharmaceuticals, Inc.	4.66%	-17.37%	-50.86%	-2.39%	-3.46%
Beone Medicines Ltd	7.62%	21.35%	57.45%	78.28%	25.05%
Vertex Pharmaceuticals Incorporated	-15.87%	-17.97%	-18.14%	35.67%	45.07%
Alnylam Pharmaceuticals, Inc.	38.16%	82.49%	68.79%	112.36%	238.79%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Prothena Corporation Plc	35.44	NA	0.8	-4.59	-0.67	-0.3	NA	6.03
Regeneron Pharmaceuticals, Inc.	15.08	15.08	1.23	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.25	28.25	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Prothena Corporation Plc	Buy	$460.8M	-32.31%	35.44	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$63.4B	-3.46%	15.08	31.37%
Beone Medicines Ltd	NA	$38.2B	25.05%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.9B	45.07%	28.25	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	238.79%	NA	-12.96%

About Prothena Corporation Plc

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Organization	Prothena Plc
Employees	163
CEO	Dr. Gene G. Kinney Ph.D.
Industry	Health Technology

Key Management of Prothena Corporation Plc

Name	Title
Dr. Gene G. Kinney Ph.D.	President, CEO & Director
Mr. Tran B. Nguyen M.B.A.	CFO & Chief Strategy Officer
Mr. Brandon S. Smith	Chief Operating Officer
Dr. Wagner M. Zago Ph.D.	Chief Scientific Officer
Ms. Karin L. Walker CPA	Chief Accounting Officer & Controller
Mr. Mark C. Johnson C.F.A.	Vice President of Investor Relations
Mr. Michael J. Malecek	Chief Legal Officer & Company Secretary
Dr. Chad H. Swanson Ph.D.	Chief Development Officer

Important FAQs about investing in PRTA Stock from India :

What is Prothena Plc share price today?

Prothena Plc share price today is $8.76 as on August 23, 2025 at 1:29 AM IST at the close of the market. Prothena Plc share today touched a day high of $8.97 and a low of $8.55.

What is the 52 week high and 52 week low for Prothena Plc share?

Prothena Plc share touched a 52 week high of $22.83 and a 52 week low of $4.32. Prothena Plc stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $8.76, lower by 61.63% versus the 52 week high.

How to invest in Prothena Plc Stock (PRTA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Prothena Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Prothena Plc Shares that will get you 0.1712 shares as per Prothena Plc share price of $8.76 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Prothena Plc Stock (PRTA) from India?

Indian investors can start investing in Prothena Plc (PRTA) shares with as little as ₹87.521 or $1 (as of August 24, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Prothena Plc stock (as per the Rupee-Dollar exchange rate as on August 24, 2025). Based on Prothena Plc share’s latest price of $8.76 as on August 23, 2025 at 1:29 AM IST, you will get 1.1416 shares of Prothena Plc. Learn more about fractional shares .

What are the returns that Prothena Plc has given to Indian investors in the last 5 years?

Prothena Plc stock has given -32.31% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?